Opdivo and Embolism - a phase IV clinical study of FDA data

Summary:

Embolism is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Yervoy, and have Non-small cell lung cancer recurrent.

The phase IV clinical study analyzes which people have Embolism when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Embolism?

Embolism (obstruction of an artery, typically by a clot of blood or an air bubble) is found to be associated with 695 drugs and 923 conditions by eHealthMe. Check the latest studies of Embolism.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 29 people (0.05%) have Embolism.

Among these 29 people:

How long have people been on Opdivo when they have Embolism? *

What is the gender of people who have Embolism when taking Opdivo? *

female: 48 %
male: 52 %

What is the age of people who have Embolism when taking Opdivo? *

What are other drugs people take besides Opdivo? *

Yervoy: 9 people, 31.03%
Carboplatin: 4 people, 13.79%
Oxycontin: 2 people, 6.90%
Buprenorphine: 2 people, 6.90%
Dexamethasone: 2 people, 6.90%
Famotidine: 2 people, 6.90%
Venlafaxine Hydrochloride: 2 people, 6.90%
Allopurinol: 2 people, 6.90%
Paclitaxel: 2 people, 6.90%
Pemetrexed: 2 people, 6.90%

What are other side effects people have besides Embolism? *

Fever: 6 people, 20.69%
Dyspnea (difficult or laboured breathing): 6 people, 20.69%
Malignant Neoplasm Progression (cancer tumour came back): 5 people, 17.24%
Skin Blushing/flushing (a sudden reddening of the face, neck): 3 people, 10.34%
Erythema Multiforme (a type of hypersensitivity reaction): 3 people, 10.34%
Pulmonary Embolism (blockage of the main artery of the lung): 3 people, 10.34%
Rashes (redness): 3 people, 10.34%
Infusion Related Reaction: 3 people, 10.34%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 3 people, 10.34%
Infection: 3 people, 10.34%

What are the existing conditions these people have? *

Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 7 people, 24.14%
Gastric Cancer (stomach cancer): 5 people, 17.24%
Oral Cancer (mouth cancer): 4 people, 13.79%
Lung Cancer - Small Cell (lung cancer): 3 people, 10.34%
Renal Cell Carcinoma (a kidney cancer): 2 people, 6.90%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 6.90%
High Blood Pressure: 2 people, 6.90%
Depression: 2 people, 6.90%
Pain: 1 person, 3.45%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Embolism?

- Check whether Embolism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Embolism treatments and more:

Embolism (13,418 reports)

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Embolism:

Embolism (695 drugs)

Browse all the conditions that are associated with Embolism:

Embolism (923 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.